Intrinsic subtype-associated changes in the plasma proteome in breast cancer

Proteomics - Clinical Applications

Volumn 3, Issue 11, 2009, Pages 1305-1313

  Nakshatri, Harikrishna ^a   Qi, Guihong ^a,b   You, Jinsam ^a,b   Kerry, Bemis ^a,b   Schneider, Bryan ^a,c   Zon, Robin ^d   Buck, Charles ^e   Regnier, Fred ^e   Wang, Mu ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Monarch Life Sciences   (United States)

^c Hoosier Oncology Group   (United States)

^d Northern Indiana Cancer Research Consortium   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

Breast cancer; Intrinsic subtypes; Plasma

Indexed keywords

ACUTE PHASE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPHORIN A; OROSOMUCOID; PLASMA PROTEIN; PROTEOME; SCAVENGER; SERUM AMYLOID P;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; HUMAN; IMMUNE RESPONSE; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; TUMOR GROWTH; UPREGULATION;

EID: 77951046534     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900040     Document Type: Article

References (38)

1. Badve, S., Nakshatri, H., Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J. Clin. Pathol. 2009, 62, 6-12.
2. Reis-Filho, J. S., Lakhani, S. R., Breast cancer special types: why bother? J. Pathol. 2008, 216, 394-398.
3. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T. et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869-10874.
4. Cheang, M. C., Voduc, D., Bajdik, C., Leung, S. et al., Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14, 1368-1376.
5. Nakshatri, H., Srour, E. F., Badve, S., Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr. Stem Cell Res. Ther. 2009, 4, 50-60.
6. Badve, S., Turbin, D., Thorat,M. A., Morimiya, A. et al., FOXA1 expression in breast cancer correlation with luminal subtype A and survival. Clin. Cancer Res. 2007, 13, 4415-4421.
7. Kapp, A. V., Jeffrey, S. S., Langerod, A., Borresen-Dale, A. L. et al., Discovery and validation of breast cancer subtypes. Biomed. Chromatogr. Genomics 2006, 7, 231.
8. Chuang, H. Y., Lee, E., Liu, Y. T., Lee, D. et al., Networkbased classification of breast cancer metastasis. Mol. Syst. Biol. 2007, 3, 140.
9. Paik, S., Shak, S., Tang, G., Kim, C. et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
10. Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F. et al., Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 2007, 25, 1239-1246.
11. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
12. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347, 1999-2009.
13. Garcia-Closas, M., Hall, P., Nevanlinna, H., Pooley, K. et al., Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008, 4, e1000054.
14. Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M. et al., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365, 671-679.
15. Gray, J. W., Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 2003, 4, 4-6.
16. Hynes, R. O., Metastatic potential: generic predisposition of the primary tumor or rare+ metastatic variants or both? Cell 2003, 113, 821-823.
17. Ellsworth, R. E., Seebach, J., Field, L. A., Heckman, C. et al., A gene expression signature that defines breast cancer metastases. Clin. Exp. Metastasis 2008, 26, 205-213.
18. Abramovitz, M., Leyland-Jones, B., A systems approach to clinical oncology: focus on breast cancer. Proteome Sci. 2006, 4, 5.
19. Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G. et al., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J. Am.Med. Assoc. 2006, 295, 2492-2502.
20. Hale, J. E., Butler, J. P., Gelfanova, V., You, J. S. et al., A simplified procedure for the reduction and alkylation of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal. Biochem. 2004, 333, 174-181.
21. Higgs, R. E., Knierman, M. D., Gelfanova, V., Butler, J. P. et al., Comprehensive label-free method for the relative quantification of proteins from biological samples. J. Proteome Res. 2005, 4, 1442-1450.
22. Bolstad, B. M., Irizarry, R. A., Astrand, M., Speed, T. P., A comparison of normalization methods for high-density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19, 185-193.
23. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 1995, 57, 289-300.
24. Yang, Y., Iyer, L. K., Adelstein, S. J., Kassis, A. I., Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS ONE 2008, 3, e3661.
25. Martens, L., Hermjakob, H., Jones, P., Adamski, M. et al., PRIDE: the proteomics identifications database. Proteomics 2005, 5, 3537-3545.
26. Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A. et al., Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20, 1487-1495.
27. Hanash, S. M., Pitteri, S. J., Faca, V. M., Mining the plasma proteome for cancer biomarkers. Nature 2008, 452, 571-579.
28. Hugh, J., Hanson, J., Cheang, M. C., Nielsen, T. O. et al., Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 2009, 27, 1168-1676.
29. Anderson, N. L., Polanski, M., Pieper, R., Gatlin, T. et al., The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 2004, 3, 311-326.
30. Goncalves, A., Esterni, B., Bertucci, F., Sauvan, R. et al., Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006, 25, 981-989.
31. Lin, Y., Goedegebuure, P. S., Tan, M. C., Gross, J. et al., Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J. Proteome Res. 2006, 5, 2169-2176.
32. Gao, W. M., Kuick, R., Orchekowski, R. P., Misek, D. E. et al., Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. Biomed. Chromatogr. Cancer 2005, 5, 110.
33. Pierce, B. L., Ballard-Barbash, R., Bernstein, L., Baumgartner, R. N. et al., Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 2009, 27, 3437-3444.
34. Pepys, M. B., Baltz, M. L., Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 1983, 34, 141-212.
35. Ceciliani, F., Pocacqua, V., The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr. Protein Pept. Sci. 2007, 8, 91-108.
36. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., Bronte, V., Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 2008, 222, 162-179.
37. Yu, H. R., Kuo, H. C., Sheen, J. M., Wang, L. et al., A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. Pediatr. Allergy Immunol. 2009, doi:10.1111/j.1399-3038.2008.00844.x.
38. Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M. et al., Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68, 3108-3114.